TOPICAL FORMULATION DEVELOPMENT OF A NOVEL THYMIDYLATE SYNTHASE INHIBITOR FOR THE TREATMENT OF PSORIASIS

A topical anhydrous semisolid was developed for a novel chemical entit y to maximize delivery of drug in the target organ, the skin. Excipien ts were selected based on increasing concentration of drug into the sk in and the ability to form semisolids. Using in vitro skin studies, th e semisolid product delivered approx. 3-times more drug into the skin than a previous clinical solution formulation without significantly in creasing receptor values. In vivo rat studies indicate the semisolid p roduct delivered approx. 8-times more drug than the previously tested clinical solution formulation.